Skip to content

Chronic Kidney Disease and Non-alcoholic Fatty Liver Diseases

Assessment of Chronic Kidney Disease in Non Alcoholic Fatty Liver Disease(NAFLD) Patients

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04779905
Acronym
NAFLD
Enrollment
62
Registered
2021-03-03
Start date
2021-02-28
Completion date
2021-09-15
Last updated
2021-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Diseases, NAFLD

Keywords

chronic kidney disease, NAFLD, Hepatic fibrosis

Brief summary

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide. This disease reportedly affects up to 30% of the general population in Western countries, especially in patients with metabolic syndrome, obesity, and type II diabetes. NAFLD is considered to be an independent risk factor for cardiovascular disease and there is accumulating evidence to support a causative role in the development of chronic kidney disease (CKD). So, we aim first to assess the prevalence of chronic kidney disease in NAFLD patients, secondly to detect the association between hepatic fibrosis and CKD in NAFLD patients

Detailed description

This study will be conducted on 100 patients 70 patients diagnosed to has NAFLD by ultrasonography presented to the outpatient clinic of Sohag University Hospital, and A control group of 30 healthy volunteers who looks normal on ultrasonography from February 2021 to July 2021. Methods: All included patients will be subjected to: 1. Detailed history, complete general and systemic examination . 2. BMI will be calculated as follow 3. Abdominal Ultrasonography. 4. Laboratory investigations: Fasting and post-prandial blood sugar Serum lipogram. Liver function tests. Serum creatinine, Albumin -creatinine Ratio. 5. Calculation of estimated Glomerular Filtration Rate eGFR. 6. Liver stiffness measurements to detect degree of fibrosis and measurement of the degree of steatosis using (Fibroscan) Ethical considerations: The study will be approved by The Ethical committee of Sohag Faculty of Medicine, Sohag University. The study protocol will be adherent to practice guidelines of the World Medical Association Code of Ethics (Declaration of Helsinki). After explanation about the nature of the procedures, possible complications, benefits, and steps of the study, All patients will give a written informed consent for participating in the study, performing abdominal ultrasound, taking blood samples, performing fibroscan.

Interventions

DIAGNOSTIC_TESTurinary albumbin/creatinine ratio

detection of microalbuminuria in nafld patients

Sponsors

Sohag University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
20 Years to 80 Years

Inclusion criteria

patients diagnosed to has NAFLD by ultrasonography presented to the outpatient clinic of Sohag University Hospital

Exclusion criteria

1. Diabetic patients. 2. Hypertensive patients. 3. Other causes of chronic liver disease rather than NAFLD.

Design outcomes

Primary

MeasureTime frame
prevalence of chronic kidney disease in nafld patientFebruary 2021 to July 2021
correlation of chronic kidney disease and degree of hepatic fibrosis in nafld patientFebruary 2021 to July 2021

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026